Foghorn Therapeutics (FHTX) EBT Margin (2020 - 2025)
Historic EBT Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 202.0%.
- Foghorn Therapeutics' EBT Margin rose 429000.0% to 202.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 305.82%, marking a year-over-year increase of 439200.0%. This contributed to the annual value of 383.24% for FY2024, which is 1074400.0% down from last year.
- Per Foghorn Therapeutics' latest filing, its EBT Margin stood at 202.0% for Q3 2025, which was up 429000.0% from 248.62% recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' EBT Margin registered a high of 77.85% during Q3 2023, and its lowest value of 65268.29% during Q3 2021.
- Over the past 5 years, Foghorn Therapeutics' median EBT Margin value was 509.82% (recorded in 2023), while the average stood at 4868.12%.
- As far as peak fluctuations go, Foghorn Therapeutics' EBT Margin plummeted by -548263900bps in 2021, and later soared by 648798500bps in 2022.
- Foghorn Therapeutics' EBT Margin (Quarter) stood at 3998.32% in 2021, then surged by 83bps to 690.39% in 2022, then soared by 44bps to 383.43% in 2023, then tumbled by -78bps to 682.88% in 2024, then soared by 70bps to 202.0% in 2025.
- Its last three reported values are 202.0% in Q3 2025, 248.62% for Q2 2025, and 339.73% during Q1 2025.